On October 8, CANSINOBIO fell 5.21% in regular trading, trading at HK$36.02 with turnover of HK$377 million.

The decline came after US vaccine giant Moderna plunged 8% overnight, with Citigroup downgrading Moderna to sell, triggering negative sentiment transmission across markets that weighed on Hong Kong vaccine and innovative drug stocks.

Having surged during the National Day holiday on expectations around ESMO conference data, CANSINOBIO accumulated substantial gains and faced significant short-term profit-taking pressure. The company's mRNA personalized tumor vaccine developed in partnership with DEPPUSHI BIO remains in early-stage development, leading to increased market caution regarding near-term valuation realization.

The board also noted recent ISO and market updates, with broader healthcare and CXO names under pressure as sector-wide rotation accelerated.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)